Minerva Biotechnologies Corporation
- Biotech or pharma, therapeutic R&D
Clinical-stage private company with near-term pipeline protected by IP fortress seeks investment, partnership and/or acquisition. Lead candidate is a novel & inventive ADC that effectively targets 75% of solid tumor cancers. De-Risked: 1) Antibody portion already demonstrated safe & effective in a 1st-in-human clinical trial in a CAR T format; 2) Linker-Payload already deemed novel & inventive - no prior art; 3) after internalization by cancer cells, the toxin is DXd - the gold standard. In CAR T clinical trial, our therapeutic rescued patients who had acquired resistance to many anti-cancer drugs, including Herceptin and Enhertu! Those are $3B+ per yr drugs but half acquire resistance within first year. Protected by IP fortress, represented by Wilson Sonsini.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}